LEGALDIGMLEGALDIGM
    ← Code of Federal Regulations
    Beta
    10 CFR § 35.300

    10 CFR § 35.300 — § 35.300 Use of unsealed byproduct material for which a written directive is required.

    Beta. Legal information, not legal advice. LEGALDIGM is not a law firm. Check the official source for the current text.

    Analyze this law with AI
    § 35.300 Use of unsealed byproduct material for which a written directive is required. A licensee may use any unsealed byproduct material identified in § 35.390(b)(1)(ii)(G) prepared for medical use and for which a written directive is required that is— (a) Obtained from: (1) A manufacturer or preparer licensed under § 32.72 of this chapter or equivalent Agreement State requirements; or (2) A PET radioactive drug producer licensed under § 30.32(j) of this chapter or equivalent Agreement State requirements; or (b) Excluding production of PET radionuclides, prepared by: (1) An authorized nuclear pharmacist; (2) A physician who is an authorized user and who meets the requirements specified in §§ 35.290, 35.390, or (3) An individual under the supervision, as specified in § 35.27, of the authorized nuclear pharmacist in paragraph (b)(1) of this section or the physician who is an authorized user in paragraph (b)(2) of this section; or (c) Obtained from and prepared by an NRC or Agreement State licensee for use in research in accordance with an Investigational New Drug (IND) protocol accepted by FDA; or (d) Prepared by the licensee for use in research in accordance with an Investigational New Drug (IND) protocol accepted by FDA. [67 FR 20370, Apr. 24, 2002, as amended at 68 FR 19324, Apr. 21, 2003; 71 FR 15009, Mar. 27, 2006; 72 FR 55932, Oct. 1, 2007; 83 FR 33107, July 16, 2018]

    Related guides, FAQ and contract templates